Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07188025 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ctDNA-Based Adjuvant Chemotherapy for High-Risk Rectal Cancer

Study acronym: REACT
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Eligibility criteria expanded, about 19 words Secondary endpoints: details revised at 1 of 10 entries · Site details revised at 5 of 25 sites · Collaborators revised (3) Show 3 more changesShow less
    • Secondary endpoints: details revised at 1 of 10 entries
    • Site details revised at 5 of 25 sites
    • Collaborators revised (3)
  2. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 25 · Start date changed from estimate of Oct 2025 to Oct 14, 2025 · Secondary endpoints: 8 to 10 · 1 morev2 Show 4 more changesShow less
    • Study sites: 0 to 25
    • Start date changed from estimate of Oct 2025 to Oct 14, 2025
    • Secondary endpoints: 8 to 10
    • Collaborators: 2 to 3

    See this version in full on ClinicalTrials.gov ↗

  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to investigate whether adjuvant chemotherapy can prevent disease recurrence in patients with high-risk rectal cancer who have detectable ctDNA after surgery. The main research question the REACT study aims to answer is: \- Does adjuvant chemotherapy improve disease-free survival in patients with high-risk rectal cancer with detectable ctDNA after surgery? Interventions: \- Patients with detectable ctDNA after surgery and randomised to the experimental group will be offered adjuvant chemotherapy (4 cycles CAPOX/6 cycles FOLFOX) within 12 weeks after surgery.
Trial Details
NCT Number NCT07188025
Lead Sponsor Erasmus Medical Center
Collaborators: Prospectief Landelijk CRC Cohort (PLCRC), Dutch Colorectal Cancer Group, BOOG Study Center
Conditions Rectal Cancer
Enrollment 103 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov